MCID: ANL011
MIFTS: 31

Anal Canal Carcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Anal Canal Carcinoma

Aliases & Descriptions for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 12 13 42 14
Carcinoma of Anal Canal 12 69
Anal Canal and Perianal Gland Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6126
MeSH 42 C563020
NCIt 47 C7489
SNOMED-CT 64 285310000
ICD10 33 C21.1
UMLS 69 C0563211

Summaries for Anal Canal Carcinoma

Disease Ontology : 12 An anal canal cancer that derives from epithelial cells.

MalaCards based summary : Anal Canal Carcinoma, also known as carcinoma of anal canal, is related to anal carcinoma in situ and anal canal squamous cell carcinoma. An important gene associated with Anal Canal Carcinoma is NME1 (NME/NM23 Nucleoside Diphosphate Kinase 1). The drugs Oxaliplatin and interferons have been mentioned in the context of this disorder. Affiliated tissues include skin and prostate, and related phenotype is neoplasm.

Related Diseases for Anal Canal Carcinoma

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to Anal Canal Carcinoma

Symptoms & Phenotypes for Anal Canal Carcinoma

MGI Mouse Phenotypes related to Anal Canal Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDKN2A GLI1 NME1 NQO1

Drugs & Therapeutics for Anal Canal Carcinoma

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2 interferons Phase 4,Phase 1
3 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
4 Adjuvants, Immunologic Phase 4,Phase 1
5 Vaccines Phase 4
6 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
7
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
8
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
11 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
13 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
14 pancreatic polypeptide Phase 3,Phase 1
15 Analgesics Phase 3
16 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
17 Adjuvants, Anesthesia Phase 3
18 Narcotics Phase 3
19 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Peripheral Nervous System Agents Phase 3,Phase 2
25 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
27 Central Nervous System Depressants Phase 3
28
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
29
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
30
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
31
Palonosetron Approved, Investigational Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
32
Succinylcholine Approved Phase 2 306-40-1 5314
33
Pembrolizumab Approved Phase 2 1374853-91-4
34
Daratumumab Approved Phase 1, Phase 2 945721-28-8
35
nivolumab Approved Phase 1, Phase 2 946414-94-4
36
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
37 Immunoglobulins Phase 2,Phase 1
38 Antibodies, Monoclonal Phase 2,Phase 1
39 Antibodies Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
41
Serotonin Phase 2 50-67-9 5202
42 Serotonin Agents Phase 2
43 Serotonin Antagonists Phase 2
44 Neurotransmitter Agents Phase 2
45 Albumin-Bound Paclitaxel Phase 2,Phase 1
46 Antimitotic Agents Phase 2,Phase 1
47 taxane Phase 2
48 Neuromuscular Agents Phase 2
49 Neuromuscular Blocking Agents Phase 2
50 Neuromuscular Depolarizing Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 55)
id Name Status NCT ID Phase
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
2 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Not yet recruiting NCT03051516 Phase 4
3 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4
4 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3
5 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
7 Vectibix for the Treatment of Anal Cancer Unknown status NCT01285778 Phase 2
8 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2
9 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2
10 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2
11 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Completed NCT00903396 Phase 2
12 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2
13 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Recruiting NCT02402842 Phase 2
14 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
15 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
16 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2
17 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Recruiting NCT02560298 Phase 2
18 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
19 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
20 Nivolumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Active, not recruiting NCT02314169 Phase 2
21 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Active, not recruiting NCT00754078 Phase 2
22 Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal Active, not recruiting NCT02399813 Phase 2
23 Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers Terminated NCT01382745 Phase 2
24 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2
25 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Unknown status NCT00003867 Phase 1
26 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
27 Interleukin-12 in Treating Patients With Cancer in the Abdomen Completed NCT00003046 Phase 1
28 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1
29 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
30 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
31 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1
32 Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1
33 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
34 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
35 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
36 Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity Completed NCT00003548 Phase 1
37 Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer Completed NCT00003439 Phase 1
38 Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer Terminated NCT01324141 Phase 1
39 Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma Unknown status NCT01702116
40 Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer Completed NCT00325871
41 A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia Completed NCT02189161
42 A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System Completed NCT01970787
43 Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions Completed NCT02418494
44 Cancer in Patients With Gabapentin (GPRD) Completed NCT01236053
45 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
46 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383
47 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Recruiting NCT01845779
48 Individual Following in Anal Cancer With PET/CT Recruiting NCT02697084
49 Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma Recruiting NCT01858025 Early Phase 1
50 Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer Recruiting NCT02379039

Search NIH Clinical Center for Anal Canal Carcinoma

Cochrane evidence based reviews: anal canal carcinoma

Genetic Tests for Anal Canal Carcinoma

Anatomical Context for Anal Canal Carcinoma

MalaCards organs/tissues related to Anal Canal Carcinoma:

39
Skin, Prostate

Publications for Anal Canal Carcinoma

Articles related to Anal Canal Carcinoma:

(show top 50) (show all 67)
id Title Authors Year
1
Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. ( 27976366 )
2016
2
Anal Canal Carcinoma in a Child With Disorders of Sex Development. ( 27037640 )
2016
3
Shifting paradigm in the management of anal canal carcinoma. ( 25432583 )
2015
4
Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? ( 25976929 )
2015
5
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. ( 25903798 )
2015
6
Reply to phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243421 )
2014
7
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. ( 24472223 )
2014
8
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243447 )
2014
9
Changing patterns of anal canal carcinoma in the United States. ( 23509304 )
2013
10
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. ( 24674573 )
2013
11
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 23674135 )
2013
12
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. ( 22529257 )
2012
13
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. ( 21395883 )
2012
14
Chemotherapy in the treatment of anal canal carcinoma. ( 22658644 )
2012
15
Endobronchial metastases of anal canal carcinoma. ( 22055765 )
2012
16
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. ( 21775274 )
2011
17
Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution. ( 22331724 )
2011
18
Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. ( 20472349 )
2011
19
Anal canal carcinoma treatment results: the experience of a single institution. ( 21403412 )
2011
20
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. ( 21772841 )
2011
21
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. ( 19399614 )
2010
22
Post burn Marjolin's ulcer in the natal cleft mimicking anal canal carcinoma: a rare site. ( 21160444 )
2010
23
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( 20492729 )
2010
24
Conformal external beam radiotherapy in the treatment of anal canal carcinoma: a retrospective study of a genital organ sparing technique. ( 19695047 )
2009
25
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). ( 18191265 )
2008
26
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( 18490648 )
2008
27
Chemotherapy and radiotherapy for anal canal carcinoma. ( 18812528 )
2008
28
Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. ( 18505075 )
2008
29
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. ( 18005443 )
2007
30
External beam radiotherapy plus brachytherapy boost in treatment of anal canal carcinoma. ( 17988027 )
2007
31
The aspects of angiogenesis in anal canal carcinomas compared with that in colorectal carcinomas. ( 18060184 )
2007
32
Anal canal carcinoma with Pagetoid spread: report of a case. ( 16794808 )
2006
33
Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. ( 16631268 )
2006
34
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. ( 15752894 )
2005
35
Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. ( 15890590 )
2005
36
Epidermal growth factor receptor expression in anal canal carcinoma. ( 15923158 )
2005
37
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. ( 12788191 )
2003
38
Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life. ( 11398611 )
2001
39
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. ( 11395235 )
2001
40
Analysis of a follow-up program for anal canal carcinoma. ( 11484975 )
2001
41
Prognostic impact of CD31 antigen expression in anal canal carcinoma. ( 11677963 )
2001
42
An unusual late radiotherapy-related complication requiring surgery in anal canal carcinoma. ( 10914830 )
2000
43
Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. ( 11277325 )
2000
44
nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis? ( 10914829 )
2000
45
Patterns of recurrence in anal canal carcinoma. ( 10982516 )
2000
46
Human papillomavirus infection and p53 nuclear overexpression in anal canal carcinoma. ( 10374676 )
1999
47
Correlation between nm23-H1 overexpression and clinicopathological variables in human anal canal carcinoma. ( 10523705 )
1999
48
Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. ( 10435803 )
1999
49
The prevalence of p53 immunoreactivity in anal canal carcinoma. ( 9769387 )
1998
50
Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases? ( 9559628 )
1998

Variations for Anal Canal Carcinoma

Expression for Anal Canal Carcinoma

Search GEO for disease gene expression data for Anal Canal Carcinoma.

Pathways for Anal Canal Carcinoma

GO Terms for Anal Canal Carcinoma

Biological processes related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 8.8 CDKN2A NME1 TENM1

Molecular functions related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 8.62 GLI1 NME1

Sources for Anal Canal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....